Mantle cell lymphoma patient experience study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects patient perspectives on mantle cell lymphoma care. It does not test a treatment, so it may help researchers understand what matters most to patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with mantle cell lymphoma
- No serious medical or mental health condition that would make participation difficult
- Able to understand and sign a consent form
- Not currently in another treatment trial
- No active infection
- No substance abuse that would interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of chemotherapy and targeted therapy as a first treatment for mantle cell lymphoma. It uses special scans (PET-CT) and blood tests (MRD) to guide treatment decisions and aims to improve outcomes while reducing side effects.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.